3:43 PM
 | 
Jan 10, 2018
 |  BC Extra  |  Company News

Lipocine takes after-hours hit on negative panel vote

Lipocine Inc. (NASDAQ:LPCN) fell $1.88 (54%) to $1.58 in after-hours trading Wednesday on news that FDA's Bone, Reproductive and Urologic Drugs Advisory Committee voted 13-6 that the benefit-risk profile of Tlando testosterone undecanoate is not acceptable to support its approval to treat hypogonadism. Its PDUFA date is May 8.

In a briefing...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >